While a verdict holds, its return keeps accumulating from the day the call was made — it resets only when the verdict itself changes.
Click any date below to read that write-up
WaitSell· Aug 22, 2026
The prior WAIT hinged on a technical trigger (weekly close above 314.50 on above-average volume) that never fired: price closed at 312.70 with volume at 0.89× the 10-week average. This panel\’s deeper scrutiny surfaced the -5.3× OCF/NI ratio and the EPS decline of 9.3% YoY, fundamental risks the prior article\’s technical-only framework was not designed to capture. The shift from WAIT to SELL reflects the discovery that at an essentially unchanged price, the stock\’s underlying earnings quality is weaker than the prior setup assumed.
Why the panel isn’t ready to call DNB yet — and where they disagree.
WaitMEDIUM confidence
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
Oslo Børs (OSL) · Financials / Banking · 2026-07-14 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
Wait
MEDIUM confidence
Why
Norway's largest bank faces cyclical margin compression on strong earnings today. Fortress capital (CET1 17.4%), insider buying, and 6% yield are genuine. But five of seven investors say fair price ≠ buy now — wait for Q3 confirmation (Oct 21) or a pullback to NOK 260–280. The panel is united on quality, split on timing.
Level to watch
Key support 282.7
−4.3% from 295.3
The panel's take
Verdict: WAIT · Conviction: MEDIUM · Last price: NOK 295.3 (July 14, 2026)
DNB reported Q2 2026 earnings today — net interest income fell NOK 167 million quarter-on-quarter on margin compression (NIM down to 1.70% from 1.74%), but fee income rose 4.6% year-over-year and ROE held at a healthy 14.6% on fortress capital (CET1 17.4%, nearly double regulatory minimums). The panel's verdict is: good business, fair price, wait for confirmation. Two investors (The Moat Compounder, The Asymmetric Bargainer) say buy now; four say wait for Q3 earnings (Oct 21) or a pullback to NOK 260–280; one (The Intrinsic-Value Modeler) leans cautious, valuing fair value at NOK 263 (−12% downside). All agree the balance sheet is pristine, management is disciplined, and insider buying validates confidence — but "fair price" for a 14.6% ROE bank is not the same as a margin-of-safety price. The shortage of conviction reflects a simple split: are you paying up now for cyclical margin recovery five weeks away, or do you wait for proof and a better entry? Five of seven frameworks answer "wait."
Key levels
Key levels · DNB
NOK · as of 2026-07-14
Analyst consensus 303.7
R1313.6+6.2%52-week high / technical break
S1282.7−4.3%200-day MA / uptrend support
S2260−12.0%Value-investor conviction zone
S3200−32.3%Through-cycle fair value
NOW295.3
Analyst consensus target 303.7 NOK · range 200–350
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Resistance: The 52-week high at NOK 313.6 is the first overhead shelf; the stock barely moved on today's NII miss, showing uptrend resilience. A break and hold above 314 would signal bullish technical confirmation and likely attract momentum into the Q3 earnings catalyst (Oct 21). Round-number projection levels sit near NOK 320–330, though a parabolic-top formation has little historical overhead structure.
Current price: NOK 295.3 (July 14, 2026, on the day of earnings) sits comfortably inside the uptrend (~5.6% above the 200-day MA), pricing in fair value for a quality Nordic bank with a 6% yield. No margin of safety at this level per The Margin-of-Safety Hunter's framework (13% vs the 20–25% required); modest −12% downside per The Intrinsic-Value Modeler's DCF.
Support: The 200-day MA at NOK 282.7 is the first-line uptrend support; loss of this level would signal trend break and likely open a deeper pullback. Secondary support clusters at NOK 260–280, where value-oriented investors seek conviction entry (20–25% margin of safety restores). Through-cycle fair value (normalized margins, normalized earnings) sits deeper still, NOK 200–250, representing the "terminal value" if NIM compression proves structural rather than cyclical.
Analyst consensus: Consensus target spans NOK 200 (bubble call) to NOK 350 (bull call), averaging NOK 303.7 — notably below the current price, implying consensus is chasing the move rather than leading. The Intrinsic-Value Modeler models NOK 263 base case (−12% downside). The wide target spread reflects genuine disagreement about whether the repricing catalyst (Q3 Oct 21) validates management's margin-recovery thesis.
Key catalyst timing: Q3 earnings on October 21 will either validate the repricing story (NII re-accelerates QoQ) and likely test R1/R2 levels, or confirm margin-pressure continues and open the S2 pullback zone.
What legendary investors think
We ran DNB past a panel of seven legendary investors' frameworks.
The panel · 7 investors
🟢
2
Bullish
⚫
5
Neutral
🔴
0
Bearish
InvestorLensSignalConviction
The Moat CompounderValue🟢 Bullish70%
"The market confuses cyclical margin squeeze with permanent business damage. The moat — #1 in Norway — is intact. Management is doing exactly what I want: rising dividends, buybacks from real surplus, not chasing growth for its own sake. Fair price for quality; at NOK 295 you're paying a fair price for a good business, not a bargain price. But the 6% yield makes it reasonable for patient income holders."
The Asymmetric BargainerDhandho🟢 Bullish72%
"Heads I win: NII recovers in Q3, buyback shrinks the float, I collect 6% while re-rating happens. Tails I don't lose much: fortress balance sheet at 1.48x book, 99.4% clean loans, CET1 cushion double regulatory minimums. Chair, board members, and management all bought 161k+ shares at NOK 286–291 in May–June — that's coordinated confidence from people who know the loan book. Dhandho score 7/10: good odds, real edge, capital preserved either way."
The Quality RationalistValue⚫ Neutral60%
"Good business, fair price, not a bargain. I want three quarters of ROE above 15% before calling this 'wonderful' — it's currently 14.6%, below my threshold. Or a pullback to NOK 220–240 giving me the 25–40% discount I require. At roughly 10x earnings on a 14.6% ROE, you're paying fair value, maybe a touch rich. The 6% yield softens the blow of waiting, but this isn't the fat pitch I'd swing hard at."
The Margin-of-Safety HunterMargin of Safety⚫ Neutral58%
"Checklist score: 5/8 passes (middling). Fair value by intrinsic-value formula NOK 339 vs current NOK 295 = 13% margin of safety (thin; I want 20–25%). Earnings are cyclical — normalized mid-cycle P/E likely 11–12x, not the flattering 10x on peak-adjacent earnings. Fortress capital is a plus; dividend record is solid (COVID suspension in 2020 was industry-wide). Bullish trigger: decline to NOK 260–270 OR proof that compression stabilizes."
The GARP OperatorGARP⚫ Neutral58%
"This isn't a growth stock — it's a Slow Grower / Sluggard. No ten-bagger here. Earnings declining ~6–9% YoY; PEG is inapplicable with negative growth. The right question: is 10.7x P/E + 6% yield adequate compensation for the decline? Every quarter I'd verify that fee income growth (+4.6% YoY) offsets NIM erosion. If the offset breaks, dividend coverage tightens and I reassess. Mature market, dominant incumbent — this is income-and-patience, not a compounder."
The Macro OpportunistMacro & Technicals⚫ Neutral55%
"This is a rate-cycle-inflection trade, not a rate-cut trade. Norges Bank has one more hike (Aug 2026), then cuts in 2027. The repricing is specific and dateable (July 12 → Q3 earnings Oct 21). Uptrend intact — price +5.6% above 200-day MA, stock barely moved on today's miss. But R/R is mediocre at current price (1.3–1.7:1); better on pullback to 200-day (2.5:1). I'd trim at current levels and accumulate on weakness into Oct 21 confirmation."
The Intrinsic-Value ModelerDCF⚫ Neutral55%
"My excess-return DCF fair value: NOK 263 (−12% downside at current). Market already priced in the bull case (Q3 recovery + Nov CMD uplift). Valuation hinges on one assumption: how much of current 14.6% ROE is cyclical vs structural? Everything else moves by single digits; this moves by 30%+. Sensitivity: bear NOK 215 (ROE → 8.5%), base NOK 263 (ROE fade 14%→9%), bull NOK 319 (NII stabilizes, targets raised). I'd rather wait for Q3 confirmation or a pullback before conviction sizing."
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
The numbers right now are genuinely strong: ROE 14.6%, NIM held despite Q2 pressure, fee income +4.6% YoY, CET1 17.4%, 99.4% Stage 1/2 loans — a fortress balance sheet with operational strength.
Margin compression is cyclical, not structural: rate-driven (July 12 repricing, Aug 2026 potential hike), not credit-driven; banks have navigated this many times before.
Management is disciplined: rising dividend, buybacks from real surplus capital (not financial engineering), insider buying validates confidence.
Q3 earnings (Oct 21) and November Capital Markets Day are the catalysts: these will either validate the margin-recovery thesis or confirm the bears' worry that structural headwinds persist.
The 6% yield is doing real work: dividend + buyback provide a return floor while you wait for clarity.
The real debate
Fair price vs. margin-of-safety price: Bulls (The Moat Compounder, The Asymmetric Bargainer) say NOK 295 is fair-to-cheap; cautious investors (The Margin-of-Safety Hunter and value-oriented investors) want NOK 260–280 (20–25% discount) before real conviction. The gap is whether you trust the repricing catalyst enough to pay full value now.
Cyclical trough or structural shift: Everyone agrees margins compressed; they disagree whether Q3 proves the trough is near or shows further deterioration. Management says July 12 repricing will support Q3 NII — that's the next five weeks' story.
Earnings durability: Intrinsic-Value Modeler says normalized through-cycle margin is lower than today's 1.70%; mid-cycle is ~1.1–1.2%; GARP Operator says fee income offset is temporary. Bull view is both pressure and offset normalize at higher absolute levels.
Entry timing: Two say buy now (insider confidence, fortress balance sheet); four say wait (better entry or confirmation needed); one leans cautious on valuation. The consensus is not "pass" — it's "wait for data."
The question it comes down to: Do you trust the Q3 repricing catalyst and pay fair value now, or do you wait for confirmation and potentially get a better entry in the NOK 260–280 zone? Five of seven frameworks say "wait."
The numbers
Metric
Value
Assessment
Price / Market cap
NOK 295.3 / NOK 460B ($43B USD)
Current day of earnings; recent range NOK 282–315
P/E (TTM)
~10.7x
Fair for quality; not cheap vs Nordic peers (Nordea ~11.5x, SEB ~13x)
P/B
1.48x
In-line with Nordic banks; no bargain relative to ROE ranking
ROE (Q2)
14.6%
Down from 16.6% (Q4 2025); below 15% "excellent" threshold
Dividend Yield
6.0%
Solid; payout ratio 58–63% (sustainable, covers earnings)
Down from 1.74% (Q1); spreads compressing (1.73% Q3 2025 → 1.52% Q1 2026)
Fee Income Growth (YoY)
+4.6%
Genuine offset to NII pressure; diversification working
Insider Buying (H1 2026)
161k+ shares @ NOK 286–291
Chair, board, management all buying — bullish signal
Analyst Consensus Target
NOK 303.7
~1.8% upside; "Hold" consensus; minimal new conviction
Figures from DNB Q2 2026 (quarter ended June 30, reported July 14) / current pricing mid-day July 14, 2026; sourced from DNB IR, Investing.com, stockanalysis.com, Stockopedia. Through-cycle fair values per investor models: The Quality Rationalist ~NOK 220–240, The Margin-of-Safety Hunter NOK 260–270, The Intrinsic-Value Modeler NOK 263, The Macro Opportunist ~NOK 200–250. Current price reflects all known earnings data.
The bottom line
DNB is the panel's clearest "quality at fair price" call — and the caution comes despite genuinely impressive numbers. The fortress balance sheet (CET1 17.4%, 99.4% Stage 1/2), the insider buying, the 6% yield, and the management-guided repricing catalyst (July 12 → Q3 earnings Oct 21) are all real and bullish. But five of seven frameworks — value, growth, quantitative, macro, and fundamental — reach the same conclusion for the same reason: this is a cyclical margin compression in a commoditized banking market, fair price is not the same as a margin-of-safety price, and the next five weeks will either validate the recovery thesis or confirm structural headwinds persist. Normalized through-cycle fair value sits well below the current price (NOK 200–270, depending on model), consensus targets sit around NOK 303 (essentially flat), and the margin of safety at NOK 295 is thin per The Margin-of-Safety Hunter's framework (13%), modestly negative per The Intrinsic-Value Modeler (−12% to fair value). What would change the call is a Q3 earnings print showing NII re-accelerating quarter-on-quarter and a November Capital Markets Day confidence reaffirmation — at which point the four cautious investors upgrade to BUY. What keeps this a WAIT is that absent that confirmation, buyers are paying a fair price in a cyclical trough year for a business whose earnings history shows mean-revert hard when the cycle turns. The magnitude of management's insider buying and the outsized 6% yield are why conviction is Medium, not high; the direction — wait for confirmation or pullback — is not in much doubt.
This is analysis, not investment advice. Consult a qualified financial advisor before making any investment decisions.
Catalyst calendar: July 12 repricing (passed) · August 2026 potential Norges Bank hike · October 21 Q3 earnings (critical test) · November 10 Capital Markets Day (guidance reset)
Next review trigger: Q3 earnings confirmation or technical break of NOK 313.6 resistance
contact@verdixhq.com · Published 2026-07-14 · Prices as of 2026-07-14 · Time horizon: 3–12 months · Analysis reflects multi-perspective investor debate. No material conflicts; verdicts are educational synthesis, not personalized recommendations. · DNB verdict history → · Methodology →
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call DNB yet — and where they disagree.
WaitMEDIUM confidence
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
Wait
MEDIUM confidence
Why
Six investing frameworks agree DNB is a fortress bank with clean credit and disciplined insiders, but none see a bargain at NOK 296.4. Here's why the panel is unanimous on quality and unanimous on waiting.
Level to watch
Key resistance 300
+1.2% from 296.4
The panel's take
Verdict: WAIT · Conviction: MEDIUM · Last price: NOK 296.4 (July 18, 2026)
What changed since 2026-07-14:
Price: NOK 295.3 → 296.4 (+0.4%) — a spike toward NOK 300 was rejected and the stock briefly sliced through the NOK 282.7 200-day moving average before closing back near flat.
Panel: 2 of 7 → 0 of 6 now Bullish (The Moat Compounder and The Asymmetric Bargainer flipped Bullish → Neutral; The GARP Operator dropped from this week's panel) — ROE (14.6%) still trails the 15% bar and the DCF now reads negative for every remaining voice.
Trigger: Q3 earnings on October 21, or a retreat into the NOK 260–280 zone.
Verdict: WAIT (unchanged)
The fortress fundamentals are unchanged — CET1 17.4%, 99.4% Stage 1/2 loan quality, insiders buying 161k+ shares at NOK 286–291 — but the panel's own valuation math still reads thin-to-negative (13% margin of safety by one framework, roughly −12% by DCF), and NIM continues compressing (1.70% from 1.74%). Quality remains intact; price still isn't a bargain.
Key levels
Key levels · DNB
NOK · as of 2026-07-18
Analyst consensus 303.7
R2313.6+5.8%52-week high
R1300+1.2%Rejected this week
S1282.7−4.6%Key support / 200-day MA
S2260−12.3%Historical accumulation zone
S3200−32.5%Through-cycle fair value
NOW296.4
Analyst consensus target 303.7 NOK · range 200–350
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key resistance sits at the NOK 313.6 52-week high with a secondary shelf near NOK 300 that was rejected this week, key support runs from the NOK 282.7 level down through a NOK 260–280 historical accumulation zone, and the analyst consensus target of NOK 303.7 sits just above the current price.
What legendary investors think
We ran DNB past a panel of six legendary investors' frameworks.
The panel · 6 investors
🟢
0
Bullish
⚫
6
Neutral
🔴
0
Bearish
InvestorLensSignalConviction
The Moat CompounderValue/Quality/Moat⚫ NeutralMedium
"This is a fortress bank — CET1 17.4%, 99.4% Stage 1/2 loans, insiders buying 161k+ shares at NOK 286–291 — but ROE of 14.6% still falls short of my 15% bar and the DCF reads roughly −12% margin of safety at NOK 296.4. I'd rather wait for Q3 earnings (Oct 21) or a pullback to NOK 260–280 than chase a stock that just got rejected from NOK 313.6."
The Margin-of-Safety HunterDeep Value⚫ NeutralMedium
"At 10.8x trailing earnings and 17.4% CET1, this clears my conservative bar, but ROE of 14.6% falls short of the 15% excellence mark and NIM slipping to 1.70% from 1.74% is earnings-quality erosion that warrants patience. NOK 296.4 sits far closer to the NOK 313.6 high than the NOK 260–280 value zone, and the DCF itself reads a negative 12% margin of safety."
The Quality RationalistQuality/Mental Models⚫ NeutralMedium
"DNB is a wonderful business, but at NOK 296.4 and roughly 10.8x earnings for a 14.6% ROE bank still short of my 15% threshold, I'm not paying up. This week's round trip through the NOK 282.7 moving average and back to 296.4 is noise on top of a thesis unchanged since last week — I want a pullback to 260–280 or Q3 confirmation on October 21."
The Asymmetric BargainerDhandho/Contrarian⚫ NeutralMedium
"Fortress capital at 17.4% CET1, 99.4% Stage 1/2 loans, and insiders buying at NOK 286–291 — but at NOK 296.4 and roughly 10.8x earnings, this isn't a heads-I-win-big setup, it's closer to a coin flip. Margin of safety reads 13% by one framework and negative 12% by DCF — too thin to bet big until NOK 260–280 or Q3 earnings on October 21 tilts the odds back in my favor."
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMedium
"A 14.6% ROE against 17.4% CET1 is solid stewardship, but it doesn't justify 10.8x trailing earnings when my margin-of-safety framework reads negative to barely positive (13% one measure, −12% DCF). NIM compression from 1.74% to 1.70% is a small but real crack, and this week's rally to NOK 300 that couldn't hold and settled at 296.4 tells me the market is equally undecided."
The Macro OpportunistMacro/Timing⚫ NeutralLow
"Nothing's broken — CET1 17.4%, 99.4% Stage 1/2 loans — but NIM compressing to 1.70% and ROE stuck at 14.6% mean the business is decelerating into a quiet catalyst calendar until October 21. Price action this week was chop, not conviction: a spike toward 300 was rejected, and the stock sliced through the NOK 282.7 200-day MA intraweek before closing back at 296.4 against a consensus target of just NOK 303.7."
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
The balance sheet is a fortress: CET1 of 17.4% and Stage 1/2 loans at 99.4% across every framework.
Insider buying (161k+ shares at NOK 286–291) is read as a genuine confidence signal, not noise.
NIM compression (1.70% from 1.74%) and ROE at 14.6% — below the 15% "excellent" bar several voices cite — are real, if cyclical, headwinds.
The same two triggers would move the call: Q3 earnings on October 21, or a pullback into the NOK 260–280 zone.
Pause or deceleration:The Macro Opportunist frames the NIM/ROE softness as active deceleration into a quiet catalyst calendar, while The Moat Compounder and The Quality Rationalist treat the same numbers as a fortress business pausing at a fair price, not weakening.
Conviction on waiting itself: Five of six size their patience at Medium conviction; The Macro Opportunist is the outlier at Low, flagging that a consensus target of just NOK 303.7 offers little reward even for waiting well.
The question it comes down to: Does Q3 earnings on October 21 confirm the NIM compression has stabilized, reopening the case to pay today's price — or does the stock need to actually reach the NOK 260–280 zone before the numbers justify commitment?
The numbers
Metric
Value
Price / Market cap
NOK 296.4 / ~NOK 460B
P/E (TTM / fwd)
10.8x / n/a
ROE
14.6%
Operating margin
n/a
Dividend yield
6.0%
Debt / equity
n/a
Free cash flow
n/a
Figures as of July 18, 2026; sourced from DNB Q2 2026 disclosures, insider transaction filings, and current market pricing.
The bottom line
What tips this from WAIT to BUY is specific: NII re-accelerating quarter-on-quarter when DNB reports Q3 earnings on October 21, closing the gap between the panel's roughly 13%-to-negative margin-of-safety math and the 20–25% discount several value-oriented voices require. Absent that print, a retreat into the NOK 260–280 zone would independently restore the discount without needing confirmation from earnings. The Macro Opportunist's outlier Low-conviction stance is worth watching into that date — a consensus target of just NOK 303.7, barely above today's price, means even patience captures little reward if the stock grinds sideways rather than moving toward either level. Until one of those two levers moves, expect this thesis to keep re-confirming rather than resolving.
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call DNB yet — and where they disagree.
WaitMEDIUM confidence
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
Wait
MEDIUM confidence
Why
Six investing frameworks hold their ground on DNB this week: price edged up to NOK 298.7 but has now closed three straight weeks pinned at the 298–301 shelf with no volume-confirmed break above resistance. A Baltic-stake divestment and a continuing buyback register as capital-discipline footnotes rather than catalysts, while a fresh analyst target cut keeps the panel's already-thin margin-of-safety math unresolved. The debate and the key levels.
Level to watch
Key resistance 300
+0.4% from 298.7
The panel's take
Verdict: WAIT · Conviction: MEDIUM · Last price: NOK 298.7 (as of 2026-07-25)
What changed since 2026-07-18:
Price: NOK 296.4 → 298.7 (+0.78%) — three consecutive weekly closes now capped in the NOK 298–301 band on in-line, not surging, volume. This reads as coiling under resistance rather than a confirmed breakout; the latest bar's thin volume looks like a data-completeness artifact from an in-progress week, not a signal.
Panel: 0 of 6 bullish, unchanged — conviction holds at Medium for five voices and Low for The Macro Opportunist, the same split as last week. No archetype moved off Neutral.
New this week: DNB confirmed a Baltic-stake divestment (agreement to exit its Luminor holding), which brings a modest one-off accounting charge in the Q3 print alongside a small CET1 uplift; the ongoing ~1% share buyback continued through week 29 at an average purchase price near NOK 295; and Morgan Stanley cut its target to NOK 276 and reiterated its cautious rating, pulling the blended consensus target down toward roughly NOK 298–304 even as at least one other narrative nudged its own fair-value estimate up slightly.
Offsetting macro thread: Norges Bank held its policy rate steady with inflation running hot — a higher-for-longer rate path that is broadly supportive of net interest margin, cutting gently against the compression the panel has been watching, though this is a slow-moving backdrop item, not a fresh weekly catalyst.
Verdict: WAIT (unchanged)
Nothing this week resolves the standoff between quality and price. The fortress balance sheet is intact and now comes with two visible capital-discipline signals — the Luminor exit and a buyback purchasing stock around today's level — but every framework's own math still reads thin-to-negative on margin of safety, and the analyst tape moved a touch more cautious, not less. Quality remains obvious; the discount still isn't there.
Key levels
Key levels · DNB
NOK · as of 2026-07-25
R3313.6+5.0%
R2307.3+2.9%
R1300+0.4%
S1289−3.2%Recent higher-low band
S2260−13.0%Historical accumulation zone
S3200−33.0%Through-cycle fair value
NOW298.7
Key support & resistance — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
The stock is testing the top of its multi-month range rather than breaking through it: three weekly closes stuck at 298–301 with no volume expansion above the old 300 shelf, and a newly flagged NOK 307.3 shelf sitting between that level and the untouched NOK 313.6 high. Support has tightened meaningfully — the last three weekly lows (283.6, 289.1, 294.6) form a rising floor well above the older NOK 282.7 moving-average level, which now serves as a wider cushion rather than the nearest support. The analyst consensus target sits barely above spot, offering little visible reward even for patience.
What legendary investors think
We ran DNB past a panel of six investing frameworks.
The panel · 6 investors
🟢
0
Bullish
⚫
6
Neutral
🔴
0
Bearish
InvestorLensSignalConviction
The Moat CompounderValue/Quality/Moat⚫ NeutralMedium
"Nothing this week moves my math — ROE is still 14.6% against my 15% bar, and lending income just printed its lowest level in three years. The Baltic-stake sale is sensible housekeeping, not a catalyst — it doesn't touch CET1 or the earnings power I'm valuing. A wonderful business having a quiet quarter is still a wonderful business — it's just not on sale at NOK 296–299. I'm waiting for Q3 (Oct 21) or a walk into NOK 260–280."
The Margin-of-Safety HunterDeep Value⚫ NeutralMedium
"At roughly 10.8x earnings and 17.4% CET1 this clears my basic bar, but ROE of 14.6% still falls short of excellence and NIM slipping to 1.70% is a genuine crack, not noise. My own arithmetic reads thin to negative — 13% by one measure, negative 12% by DCF — and NOK 296–299 sits far closer to the NOK 313.6 high than the value zone. The margin of safety is always dependent on the price paid, and this week's fluctuation has none."
The Quality RationalistQuality/Mental Models⚫ NeutralMedium
"This is still a wonderful business trading at a fair-to-slightly-rich price, and I've never confused wonderful with cheap enough to act on. Shedding the Baltic stake for a modest one-off loss is the kind of unglamorous discipline that tells me management is managing the balance sheet, not the stock price — that's a governance point in its favor, not a fundamentals worry. I have nothing to add on the price question until either the NIM print turns or the stock does the discounting for me."
The Asymmetric BargainerDhandho/Contrarian⚫ NeutralMedium
"The balance sheet is still a fortress, and now management is putting its own capital behind the stock via a buyback purchasing near NOK 295 — a confidence tell worth banking. But this setup needs a visible gap between price and value, and at 10.8x earnings for a 14.6% ROE bank sitting a few kroner off a rejected high, the odds are close to even money, not stacked in my favor. A management buyback tells me the downside is well-defended, but it doesn't hand me the asymmetry I need to bet big."
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMedium
"A stock doesn't get cheaper just because it sits still — my DCF still reads a margin of safety somewhere between thin and outright negative, and nothing this week touches the two variables that move it: ROE (still 14.6%) or NIM (still compressing). The sell-side split confirms my own ambivalence, and the blended consensus target is barely above today's price. A story doesn't need to change for the value story to stay unresolved — it just needs the price and the fundamentals to keep moving in lockstep, which is exactly what happened this week."
The Macro OpportunistMacro/Timing⚫ NeutralLow
"Rates held steady with inflation running hot — a backdrop that's broadly supportive of margin but hasn't stopped competition from dragging lending income to a three-year low. The buyback and the Baltic-stake write-down both land right around the October 21 print, which is where I'm watching for a real signal. A buyback into a stock sitting below its own consensus target is a company telling you it doesn't think the market's mispriced it much lower — that's a floor signal, not a catalyst."
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
The balance sheet remains a fortress — CET1 at 17.4% with no credit-quality deterioration this week.
The Baltic-stake divestment and its modest one-off Q3 accounting charge is read across the panel as capital-discipline housekeeping, not a fundamentals concern.
The ongoing share buyback (purchasing near NOK 295) is treated as a management confidence signal, not a re-rating catalyst.
The same two triggers would move every voice off Neutral: Q3 earnings on October 21, or a retreat into the NOK 260–280 zone.
What the buyback actually signals:The Asymmetric Bargainer and The Macro Opportunist treat the buyback as a defended-downside "floor" worth banking, while The Moat Compounder treats the same program as routine housekeeping that doesn't touch the valuation case either way.
Conviction on waiting itself: five of six size their patience at Medium; The Macro Opportunist stays the outlier at Low, still flagging a consensus target barely above spot as thin reward even for waiting well.
The question it comes down to: Does Q3 earnings on October 21 — landing the same quarter as the Baltic-stake accounting charge — confirm NIM has actually stabilized, reopening the case to pay today's price, or does the stock still need to reach the NOK 260–280 zone before the numbers justify commitment?
The numbers
Metric
Value
Price / Market cap
NOK 298.7 / ~NOK 460B
P/E (TTM / fwd)
~10.7x / n/a
ROE
14.6%
Operating margin
n/a
Dividend yield
~6.0%
Debt / equity
n/a
Free cash flow
n/a
Figures as of 2026-07-25; sourced from DNB Q2 2026 disclosures, DNB buyback status filings (week 29, 2026), and current market pricing via TradingView, stockanalysis.com, and MarketScreener consensus data.
The bottom line
What tips this from WAIT to BUY is unchanged in kind, if slightly sharpened in timing: NII re-accelerating when DNB reports Q3 earnings on October 21 — a print now carrying an extra wrinkle, since the Baltic-stake accounting charge lands the same quarter and could create a headline-driven dip that some frameworks would treat as a technical buying opportunity rather than a fundamentals problem. Absent that, a retreat into the NOK 260–280 zone would independently restore the discount without needing earnings confirmation. The ongoing buyback purchasing stock near today's price is a genuine floor signal worth tracking, but the panel is unanimous that it doesn't substitute for the 20–25% discount several value-oriented voices still require. Until one of those two levers moves, or the stock actually clears the newly identified NOK 307.3 shelf on volume, expect this thesis to keep re-confirming rather than resolving.
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call DNB yet — and where they disagree.
WaitHIGH confidence
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
OSL · Financials · 2026-08-01 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
Wait
HIGH confidence
Why
Five investing archetypes — spanning value, quality, and forensic frameworks — unanimously agree DNB is a best-in-class Norwegian banking franchise, yet every single one refuses to buy at ~305 NOK near all-time highs with thinning momentum and zero margin of safety. The debate isn't about the business; it's about whether patience will be rewarded with a pullback to the 260–294 zone that would turn this into a high-conviction opportunity.
Level to watch
Key resistance 307.3
+0.8% from 305
The panel's take
Verdict: WAIT · Conviction: HIGH · Last price: 305.0
What changed since 2026-07-25:
Price: 298.7 → 305.0 (+2.11%)
Panel: 0 of 6 → 0 of 5 now Bullish — composition also changed: added The Forensic Skeptic, The GARP Operator; removed The Macro Opportunist, The Margin-of-Safety Hunter, The Quality Rationalist
Trigger: BUY trigger: pullback to 260–294 NOK (P/B ~1.3, P/E ~9–10x, weekly EMA20/EMA50 zone — the margin-of-safety band cited by The Moat Compounder, The Forensic Skeptic, The Asymmetric Bargainer, and The GARP Operator) OR a high-volume weekly close above 313.60 confirming the ATH breakout. SELL trigger: monthly MACD histogram turning negative (bearish cross) would signal the multi-year trend has broken and reclassify this to SELL.
Verdict: WAIT (unchanged)
The prior panel (July 25, price 298.7) delivered a MEDIUM-conviction WAIT; since then, the stock has crept 2.1% higher to 305, thinning momentum further as the monthly MACD histogram flattened to zero. The addition of The Forensic Skeptic and The GARP Operator to this panel surfaced the volume-at-ATH problem that the earlier panel missed — a new, independently verified reason for caution — which is why conviction stepped up to HIGH despite the business story remaining unchanged.
Unanimous agreement: DNB is a high-quality franchise with a wide moat, but all five voices reject buying at the current ~305 NOK near all-time highs with thinning momentum and negative margin of safety. This is a BUY-vs-WAIT split with zero BUY voices — not a HOLD, because no voice disputes the business itself. Every objection is price/timing, which the panel's synthesis approach maps to WAIT.
Key levels
Key levels · DNB
NOK · as of 2026-08-01
R2313.6+2.8%
R1307.3+0.8%
S1293.91−3.6%
S2284−6.9%
S3260−14.8%
NOW305
Key support & resistance — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran DNB Bank ASA past a panel of 5 legendary investors' frameworks.
The panel · 5 investors
🟢
0
Bullish
⚫
5
Neutral
🔴
0
Bearish
InvestorLensSignalConviction
The Moat CompounderValue/Quality/Moat⚫ NeutralMed
Signal: DNB's 27% market share, 17.9% CET1 ratio, and 6% dividend yield make it a high-quality franchise with a wide moat, but at a P/E of 10.9 and P/B of 1.56, the stock is trading at a fair price, not a wonderful one — I'd need a 25–30% discount to intrinsic value, around NOK 260, to act. Conviction: Conviction is restrained by price alone: the business quality, management's capital-allocation track record, and fortress balance sheet are all independently verified strengths, but the absence of a margin of safety means the framework cannot convert admiration into a buy.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralLow
Signal: My two-stage residual income model — assuming ROE declines from 14.6% to 12% over five years against an 8.5% cost of equity — produces a base-case value of NOK 335, yet at a P/B of 1.56 and P/E of 10.9 the market is already pricing in exactly the gradual ROE decline I forecast, leaving only a ~10% gap that is too narrow to act on with 55% confidence. Conviction: Conviction is held in check by the tight fit between market price and intrinsic value across all three scenarios — the bear, base, and bull cases span a range that all produce roughly fair pricing, so there is no independent valuation signal screaming mispricing.
The GARP OperatorGrowth (GARP)⚫ NeutralMed
Signal: DNB's 6% dividend yield plus 3% near-term growth points to a ~9% annual total return — reasonable for a Stalwart at 10.9x earnings — but the monthly MACD histogram is flat at zero and the stock is pressing all-time highs on zero volume, a classic warning flag that says 'wait for a pullback to the weekly EMA20/EMA50 zone at 284–294'. Conviction: Conviction is held back because the technical signal and the fundamental signal are in conflict: the business is solid and the buyback is a bullish counterpoint, but the thinning momentum at the highs is an independent, hard-to-ignore caution that no amount of earnings quality can override.
The Forensic SkepticContrarian/Forensic⚫ NeutralMed
Signal: I read the filings and found no hidden liabilities, no accounting games, and no off-balance-sheet sinkholes — this is a boring, well-run bank — but at NOK 305 the stock offers a negative margin of safety against my weighted intrinsic value of ~290, and the nearest thick volume support sits 47% lower at 207, meaning the 6% dividend yield does not compensate for a 20–30% mean-reversion risk. Conviction: Conviction is unusually high in the “don’t buy” direction because three independent signals — fair fundamental value, exhausted monthly momentum, and thin volume above the all-time high — all converge on the same conclusion: the setup is unfavorable.
The Asymmetric BargainerContrarian/Deep Value⚫ NeutralMed
Signal: DNB passes three of four Dhandho tests — simple business, limited downside, favorable odds — but the base case offers only 15–30% upside over two to three years, nowhere near the 2–3x return that Dhandho demands, so I pass at 305 and wait for a fat pitch at 260–270 where the downside shrinks to 10–15% and the upside expands to 50%+. Conviction: Conviction in waiting is reinforced because uncertainty is low but asymmetry is also low: the market is not terrified of Norwegian banks, so there is no wide chasm between perception and reality to exploit.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
All five archetypes agree DNB is a high-quality franchise with a genuine economic moat — its 27% Norwegian market share, 17.9% CET1 ratio, and 14.6% ROE are undisputed strengths.
All five agree the stock is not a buy at the current ~305 NOK: every voice independently concludes that the price offers either no margin of safety or insufficient upside asymmetry.
All five agree that a pullback into the 260–294 NOK range — roughly P/B 1.2–1.3, P/E 9–10x — would transform the setup into a compelling opportunity.
None of the five voices identifies any business-quality or structural risk that would warrant a sell; every objection is confined to price, timing, or technical structure.
The real debate
The Intrinsic-Value Modeler sees the market as efficiently pricing the ROE decline (fair value ~335, within noise of current price), while The Forensic Skeptic argues the stock is slightly overvalued (intrinsic value ~290, negative margin of safety) — a tension between "fairly valued, don't add" and "overpriced given the technical risk."
The Moat Compounder and The Asymmetric Bargainer both want a pullback to ~260–270 to create a margin of safety, but for different reasons: the former seeks a discount to intrinsic value for a long-term hold, while the latter needs the pullback to restore the asymmetric payoff ratio (small downside, 50%+ upside) that Dhandho requires.
The GARP Operator is the only voice giving meaningful weight to the technical setup — flat monthly MACD, zero volume at all-time highs — as an independent reason to wait, whereas The Intrinsic-Value Modeler treats technicals as mere confirmation of a fundamentally neutral picture.
The question it comes down to: Will DNB's stock price retreat to its historical accumulation zone (260–294 NOK) before the August 2026 Norges Bank rate hike and Carnegie acquisition synergies cement a fundamentally higher floor for the shares?
The bottom line
The condition that would turn this WAIT into a BUY is unambiguous: a pullback into the 260–294 NOK band, where P/B compresses to ~1.3 and the dividend yield stretches above 7%, giving all five archetypes the margin of safety they independently require. Alternatively, a high-volume weekly close above 313.60 — confirming the all-time-high breakout with real sponsorship, not thin air — would resolve the momentum question and reclassify the setup. The bear case is equally specific: watch the monthly MACD histogram; if it crosses into negative territory (a bearish cross), the multi-year trend is broken and this becomes a SELL. The August 2026 Norges Bank rate decision and Q3 earnings (particularly net interest income trajectory and Carnegie's contribution) are the dated catalysts most likely to tip the balance before year-end.
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call DNB yet — and where they disagree.
WaitMEDIUM confidence
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
OSL · Financials · 2026-08-08 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
Wait
MEDIUM confidence
Why
Six archetypes debate DNB.OL, Norway's dominant bank, split between waiting for a better entry and recognizing contrarian value at today's 10.7x earnings and 6% yield. Everyone agrees the moat is real and the dividend is safe: the fight is over whether the price already reflects the flat-earnings reality. The stock sits at a decision point, where a breakout above 313.60 NOK or a pullback to 295–300 could flip the WAIT to BUY, while a breakdown below 285 would signal the thesis is broken.
Level to watch
Key resistance 313.6
+1.8% from 308.2
Next catalyst
Breakout trigger: A decisive weekly close above 313.60 NOK with above-average volume would confirm the Stage 2 uptrend and flip the call to BUY by removing the timing objection every cautious voice shares.
The panel's take
Verdict: WAIT · Conviction: MED · Last price: 308.2
Trigger: Two triggers would flip to BUY: (1) a decisive weekly close above 313.60 NOK (all-time high) with above-average volume, confirming breakout momentum, OR (2) a pullback/mean-reversion to the 295-300 NOK support zone (weekly EMA20 at 295.68), which would provide the margin of safety the cautious voices demand. A breakdown below weekly EMA50 (285.10) on a closing basis would flip to SELL, as it would break the Stage 2 structure and signal the distribution/topping thesis.
Verdict: WAIT (unchanged)
The prior panel was a unanimous WAIT at much higher conviction: every voice saw the stock as fairly priced with no edge. This time, the addition of The Forensic Skeptic and The Structural Tailwind Rider shifts the tone, since both identify contrarian value at these levels, and even the holdouts acknowledge the buyback signals management conviction. The price has barely moved (+1.0% from 305 to 308.2), though, so the blocker is unchanged: the stock hasn't broken out above 313.60 nor pulled back to the 295–300 accumulation zone. The wait continues, but the panel is now split on whether waiting is cautious wisdom or a missed opportunity.
The split is BUY vs WAIT at its structural core. The two bullish-leaning voices (the technical read sits at BALANCED but is structurally a deferred BUY, alongside The Moat Compounder, The GARP Operator, and The Intrinsic-Value Modeler all gravitating to "great business, wrong price") point toward a high-quality franchise everyone respects. The genuine BUSINESS-objection camp is thin: only The Margin-of-Safety Hunter's pure-checklist bear case (earnings declining, bank leverage disqualifies it) pushes back hard, while The Forensic Skeptic tilts cautiously bullish. No voice condemns the franchise itself. The blocker is overwhelmingly PRICE/TIMING, with the stock sitting at all-time-high resistance (313.60) on thinning volume and multiple voices naming a pullback to 295-300 (or 250-260) as their entry. An identifiable trigger exists in either direction: a decisive break above 313.60, or a pullback to the 295-300 support zone. This is a classic BUY vs WAIT split, where everyone likes the business and the dispute is only whether to pay today's price or wait. Per Step B, a BUY vs WAIT split synthesizes to WAIT.
Key levels
Key levels · DNB
NOK · as of 2026-08-08
R1313.6+1.8%
S1295.68−4.1%
S2285.1−7.5%
S3250−18.9%
NOW308.2
Key support & resistance — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran DNB Bank ASA past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
🟢
0
Bullish
⚫
5
Neutral
🔴
1
Bearish
InvestorLensSignalConviction
The Moat CompounderValue/Quality/Moat⚫ NeutralMed
Signal: DNB is a wonderful business, a durable moat backed by a best-in-class 35% cost-to-income ratio, but at 10.7x trailing earnings with flat-to-declining EPS and the stock pressing all-time-high resistance at 313.60 NOK, the price is fair, not wonderful, and I'd need a pullback to the 250–260 NOK range before adding new money. Conviction: What holds this back is a genuine split in the signals: management is confidently buying back NOK 4.8 billion in stock, yet Goldman Sachs and UBS are both telling clients to sell, and that level of disagreement means uncertainty is high enough that the margin of safety isn't wide enough to pull the trigger.
The Margin-of-Safety HunterValue/Quantitative🔴 BearishMed
Signal: DNB passes four of six applicable checklist criteria, and a Margin-of-Safety Number of NOK 375 suggests a 17.8% margin of safety, but it still fails as a true defensive holding because it is a leveraged bank with declining earnings (-9.3% YoY), and the classic screens here were built for industrial companies, not financial institutions. Conviction: High, because two independent warnings converge: earnings are declining while the Carnegie acquisition consumed 50–70 basis points of capital without yet producing visible returns, and a 6% yield on a shrinking earnings base is not the same as a 6% yield on a growing one.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: My DCF-equivalent valuation lands at NOK 295–315 against a current price of 308, making the stock essentially fairly valued. The terminal ROE of 13% and 2% growth rate produce a fair P/B of 1.57x, only modestly above the current 1.42x, which leaves no compelling edge for either buyer or seller. Conviction: Moderate, since the bear case (NOK 245) requires an ROE drop to 11% that seems inconsistent with Norway's economic resilience and DNB's 1.2% NPL ratio, while the bull case (NOK 365) depends on unproven Carnegie synergies: the base case is solid, but sensitivity around it is wide.
The GARP OperatorGrowth (GARP)⚫ NeutralMed
Signal: This is not a ten-bagger, it's a Slow Grower with Asset Play characteristics: at 10.7x earnings with a 6.0% forward dividend yield and a 60% payout ratio, you're getting paid well to wait for a franchise that earns a 48% net margin and controls roughly a quarter of Norwegian banking. Conviction: Management put real capital behind its words here, signaling the stock is cheap via a NOK 4.8 billion buyback while preserving the state's 34% stake, and that kind of insider commitment adds weight to the thesis.
The Structural Tailwind RiderGrowth / Structural Themes⚫ NeutralMed
Signal: DNB is a fortress bank at a fair price: a 10.7x P/E for a 14%+ ROE franchise with an ironclad moat and a 6% dividend yield is a rare combination in today's expensive markets, and the buyback signals management sees value the market is missing. Conviction: Caution wins out here because there is no structural growth tailwind: this is a harvest-phase bank in a mature Norwegian economy, and the return will come mostly from dividends and reinvestment rather than capital appreciation, so the case rests entirely on patience and a multiple expansion that may never arrive.
The Forensic SkepticContrarian/Forensic⚫ NeutralMed
Signal: The market is pricing DNB as if it's in terminal decline at 10.7x earnings, but my normalized P/E of 12x on roughly 31 NOK EPS suggests an intrinsic value of 372 NOK, about 20% upside, and the Goldman Sachs downgrade combined with the 4.8 billion-krone buyback creates a classic contrarian setup where the bear case is already priced in. Conviction: No urgent near-term catalyst keeps this capped: NIM compression may persist through 2027, the Carnegie integration benefits are unproven, and credit quality, while pristine at 1.2% NPLs, is concentrated in Norwegian housing where a correction would hit hard.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
Every archetype agrees DNB possesses a genuine and durable moat: dominant Norwegian market share (~25–30%), a best-in-class cost-to-income ratio (~35%), high switching costs, and regulatory barriers that protect the franchise.
All six voices accept that earnings growth is dead for now. Revenue is declining (-1.7% YoY), EPS is shrinking (-9.3% YoY), and NIM compression from easing Norwegian rates will continue to pressure profitability through 2027.
Everyone sees the 6% dividend yield as the primary return engine and agrees it is sustainable at the current 60% payout ratio, supported by the bank's strong capital position (13–14% RAC ratio).
No archetype issues a SELL verdict. Even the most cautious voice, The Margin-of-Safety Hunter, objects on structural grounds tied to bank leverage and declining earnings, not because it believes the franchise is overvalued or deteriorating.
There is unanimous recognition that the stock is pressing against all-time-high resistance at 313.60 NOK with thinning volume, and a pullback to the 295–300 zone (weekly EMA20) would improve the upside-versus-downside balance for nearly every framework.
The real debate
The Intrinsic-Value Modeler sees fair value as essentially the current price (NOK 295–315 range), while The Forensic Skeptic calculates intrinsic value at NOK 370–420, a gap of 20–36% driven by disagreement on whether the market will ever re-rate DNB from 10.7x to 12x+ P/E. This is the core split: is the discount permanent or an opportunity?
The Moat Compounder demands a 20%+ pullback to 250–260 NOK before getting interested, whereas The GARP Operator and The Structural Tailwind Rider are comfortable accumulating at the 295–300 support zone, a roughly 15% difference in entry discipline that reflects how differently each framework tolerates buying near resistance.
The Margin-of-Safety Hunter flatly rejects DNB as an investment because banks fail its leverage and earnings-stability checks by design, while The Forensic Skeptic frames that same rejection as a contrarian signal: when rule-based frameworks screen a stock out, the remaining buyers may be underpaying for quality.
The question it comes down to: Will DNB's 6% dividend yield and dominant Norwegian moat deliver attractive total returns despite flat-to-declining earnings, or will NIM compression and the stock's proximity to all-time highs mean today's buyers get certainty of income but no margin of safety on price?
The bottom line
Breakout trigger: A decisive weekly close above 313.60 NOK with above-average volume would confirm the Stage 2 uptrend and flip the call to BUY by removing the timing objection every cautious voice shares.
Accumulation zone: A pullback to the 295–300 NOK range (the weekly EMA20 at 295.68) would satisfy The Moat Compounder, The GARP Operator, and The Forensic Skeptic, turning the current WAIT into a consensus BUY on better margin of safety.
Risk to monitor: A weekly close below 285 NOK (the EMA50) would break the Stage 2 structure, validate the distribution thesis, and flip the call to SELL: this is the line in the sand for the entire panel's technical assumptions.
Next catalyst: The Q3 2026 earnings print in late October will either confirm NIM stabilization, giving The Forensic Skeptic the catalyst it's waiting on, or show accelerating compression, which would harden The Intrinsic-Value Modeler's bear case toward NOK 245.
Structural risk: Norwegian housing represents 65–70% of DNB's loan book; a rise in non-performing loans above 2.0% (from the current 1.2%) would trigger The Margin-of-Safety Hunter's disqualification threshold and likely force a dividend cut that removes the 6% yield floor every bull is relying on.
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
Why the panel isn’t ready to call DNB yet — and where they disagree.
WaitMEDIUM confidence
A quality business, but not at today's price — the panel is waiting for a better price or a catalyst.
OSL · Financials · 2026-08-15 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
Wait
MEDIUM confidence
Why
DNB is a dominant Norwegian bank with a genuine moat, fortress capital, and surging fee income — and every analyst on this panel agrees the business is sound. But with the stock pressed against multi-year resistance at NOK 314.50 and volume dangerously thin above, the debate is purely about price and timing, not quality. A breakout or a pullback would both resolve the standoff; until one arrives, they are all waiting.
Level to watch
Key resistance 313.6
+0.2% from 313.1
Next catalyst
Breakout to confirm: A weekly close above NOK 314.50 on above-average volume removes the technical ceiling that every archetype cited and would flip the panel-wide WAIT into a BUY without requiring a pullback.
The panel's take
Verdict: WAIT · Conviction: MED · Last price: 313.1
What changed since 2026-08-08:
Price: 308.2 → 313.1 (+1.59%)
Panel: 0 of 6 → 0 of 5 now Bullish — composition also changed: added The Asymmetric Bargainer; removed The Margin-of-Safety Hunter, The Structural Tailwind Rider
Trigger: Weekly close above NOK 314.50 on above-average volume confirms breakout and removes the technical objection, converting WAIT to BUY. Alternatively, a pullback into the 279.94–285.27 support zone (monthly/weekly EMA50 confluence) restores margin of safety and would also trigger a BUY.
Verdict: WAIT (unchanged)
The prior WAIT verdict stood because the stock was already approaching resistance with a consensus that the business was sound but the entry price was wrong. Since then, price has crept 1.6% higher to sit directly against the multi-year ceiling at NOK 314.50, volume above remains dangerously thin, and the panel's composition shift — adding The Asymmetric Bargainer while losing two other voices — only reinforced the "wrong price, not wrong business" logic without introducing any new bullish urgency.
Every voice — including all five investor personas — agrees DNB is a high-quality bank with a real moat and healthy fundamentals. No voice raises a BUSINESS objection (thesis/moat/quality intact). The sole caution is universally PRICE/TIMING: the stock sits pinned against multi-year resistance at NOK 314.50 with dangerously thin volume above, making entry here a poor asymmetry. This is a textbook BUY vs WAIT split — bulls like the business, everyone else says "great company, wrong price." Per Step B, a BUY vs WAIT split synthesizes to WAIT, not BALANCED.
Key levels
Key levels · DNB
NOK · as of 2026-08-15
R2314.5+0.4%
R1313.6+0.2%
S1301.02−3.9%
S2292.69−6.5%
S3285.27−8.9%
NOW313.1
Key support & resistance — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
What legendary investors think
We ran DNB Bank ASA past a panel of 5 legendary investors' frameworks.
The panel · 5 investors
🟢
0
Bullish
⚫
5
Neutral
🔴
0
Bearish
InvestorLensSignalConviction
The Moat CompounderValue/Quality/Moat⚫ NeutralMed
Signal: DNB's dominant Norwegian market share and high customer switching costs form a real but eroding moat, and at 10.7x trailing earnings the stock sits pinned against multi-year resistance with no meaningful margin of safety for a business whose earnings are forecast to shrink 6% this year. Conviction: Conviction is held back because the moat, while present, falls short of the wide-and-durable standard required for holding indefinitely, and without insider buying or a pullback into the 260–270 zone there is no evidence management or price is offering a bargain.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: Fair value lands at roughly NOK 320 using an 8.5% cost of equity and a terminal P/E of 12x, which leaves the stock almost exactly fairly priced at NOK 313 with a range of −3% to +4% upside. Conviction: The thin volume above multi-year resistance at NOK 314.50 keeps conviction subdued because a rejection at this level could easily erase the modest upside before the earnings-recovery narrative has a chance to form.
The GARP OperatorGrowth (GARP)⚫ NeutralMed
Signal: The Q2 beat and fee-income surge of 18% year-over-year are the kind of durable growth I like to see, but analysts still project a 2% annual earnings decline over the next three years, and I cannot get excited about a stock where the earnings line is pointing down. Conviction: What keeps me cautious is the absence of insider buying at these levels, paired with a technical setup where a failed breakout at NOK 314.50 exposes a drawdown risk of roughly 25% for perhaps 10% upside.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: The gap between reported earnings and actual cash generation is the strongest signal here: free cash flow runs at 1.7x net income, which means the market is over-weighting the accounting earnings dip while the franchise quietly prints cash. Conviction: Conviction is tempered by the lack of insider buying and a wide analyst dispersion where prominent bears at Goldman and UBS carry sell ratings, meaning the contrarian thesis has no confirmation from management and the crowd is not yet panicked.
The Asymmetric BargainerContrarian/Deep Value⚫ NeutralMed
Signal: The downside is poorly defined: thin volume above NOK 314.50 with only 10.7 million shares traded versus hundreds of millions at lower levels means a failed breakout could deliver a fast, violent 20–30% drawdown, violating the 'tails I don't lose much' requirement. Conviction: The expected value is only modestly positive, the payoff distribution is too wide, and no superinvestor I would clone is making a bold statement here, so this fails the core Dhandho test of a heavily skewed bet.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
DNB is a high-quality Norwegian bank with a genuine competitive moat rooted in dominant domestic market share, high switching costs, and a fortress CET1 ratio of 18.1%.
Fee-income growth (up 18% YoY) and free-cash-flow generation (1.7x net income) are bright spots that every archetype acknowledges as real, durable positives.
No archetype sees a compelling margin of safety at the current price of NOK 313, with the stock pinned against multi-year resistance at roughly NOK 314.50.
The real debate
The Moat Compounder and The Asymmetric Bargainer both question whether the moat is wide enough to justify action, but they disagree on what would resolve that doubt: The Moat Compounder wants a 15–20% pullback to restore a margin of safety, while The Asymmetric Bargainer is content to wait for a breakout confirmation above NOK 314.50 that removes the technical overhang.
The Forensic Skeptic argues that the market is underappreciating the cash-flow quality and that the wide analyst dispersion creates fertile ground for a contrarian surprise, while The Intrinsic-Value Modeler counters that the stock is almost perfectly priced at fair value and that a breakout, not a re-rating, is required to unlock any meaningful upside.
The question it comes down to: Can DNB convert its strong fee-income momentum and dominant Norwegian franchise into a confirmed technical breakout above NOK 314.50, or will multi-year resistance and declining net interest income keep the stock range-bound?
The bottom line
Breakout to confirm: A weekly close above NOK 314.50 on above-average volume removes the technical ceiling that every archetype cited and would flip the panel-wide WAIT into a BUY without requiring a pullback.
Support zone to watch: A retracement into the NOK 279.94–285.27 zone (monthly and weekly EMA50 confluence) restores a genuine margin of safety and would turn the price/timing objection into a BUY opportunity.
Q3 2026 earnings catalyst: The next quarterly report, due in weeks, must show net interest income stabilizing or fee income sustaining its 18% growth rate; a miss on either metric would validate the consensus earnings-decline thesis and could trigger the failed-breakout scenario.
Insider signal missing: Zero insider purchases over 90 days at near-resistance pricing remains a quiet yellow flag; a meaningful open-market buy by a director or executive would signal management conviction and materially shift the panel's tone.
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.
The panel’s case against DNB — and where they disagree.
SellMEDIUM confidence
The case against outweighs the case for at today's price.
OSL · Financials · 2026-08-22 · analysis, not advice
Key levels and fundamentals figures are sourced from public market data and filings. All panel verdicts, archetype reasoning, and synthesis are AI-generated analysis.
Verdict
Sell
MEDIUM confidence
Why
A panel of six archetypes delivers a unanimous message on DNB.OL: the business quality is not in dispute, but at 312.70 NOK \— above book value, above consensus targets, and above conservative intrinsic-value estimates \— no voice argues the stock is cheap. The real debate is whether the 5\–7% overvaluation is noise (two neutrals say wait) or a setup for a drawdown when declining earnings and negative operating cash flow catch up to a thinning-volume rally (four bears say sell).
Level to watch
Key resistance 313.6
+0.3% from 312.7
Next catalyst
Trigger to confirm the breakdown: A weekly close below the EMA20 at ~298 would validate the thinning-volume rally as a failed breakout and shift the technical structure from Stage 2 uptrend to distribution.
The panel's take
Verdict: SELL · Conviction: MEDIUM · Last price: 312.7 · Changed from WAIT
Panel: 0 Bullish · 2 Neutral · 4 Bearish → SELL
What changed since 2026-08-15:
Price: 313.1 → 312.7 (-0.13%)
Panel: 0 of 5 → 0 of 6 now Bullish — composition also changed: added The Margin-of-Safety Hunter; removed none
Trigger: A pullback to the weekly EMA20 near NOK 298 that holds — where The GARP Operator and the technical framework both see a buyable dip with restored asymmetry, and where the price begins to converge with the conservative Margin-of-Safety Hunter Number (NOK 305.80) — would flip SELL to BUY. Conversely, a weekly close above 317.50 on rising volume would invalidate the resistance zone and force a re-assessment of the bear case.
Verdict: WAIT → SELL
The prior WAIT hinged on a technical trigger (weekly close above 314.50 on above-average volume) that never fired: price closed at 312.70 with volume at 0.89× the 10-week average. This panel’s deeper scrutiny surfaced the -5.3× OCF/NI ratio and the EPS decline of 9.3% YoY, fundamental risks the prior article’s technical-only framework was not designed to capture. The shift from WAIT to SELL reflects the discovery that at an essentially unchanged price, the stock’s underlying earnings quality is weaker than the prior setup assumed.
Four of six voices — The Moat Compounder, The Margin-of-Safety Hunter, The GARP Operator, and The Asymmetric Bargainer — see DNB as overvalued: a zero-growth bank (PEG 194, EPS CAGR 0.44%) trading at 1.63× book with no margin of safety, deteriorating earnings (EPS –9.3% YoY), and a consensus analyst target (NOK 310) already below the spot price. The two neutral holdouts, The Intrinsic-Value Modeler and The Forensic Skeptic, do not dispute the business quality but both object on price — The Intrinsic-Value Modeler's base case is NOK 295, The Forensic Skeptic's range is NOK 280–310 — leaving no voice arguing the stock is cheap. The prior WAIT trigger (weekly close above 314.50 on above-average volume) did not fire: price closed at 312.70 with volume at 0.89× the 10-week average, and the pullback to 279.94–285.27 was never approached. The verdict shifts because the fundamental panel's deeper scrutiny of cash-flow quality (OCF/NI –5.3× TTM) and the earnings trajectory surfaced risks the prior article's technical-only trigger framework was not designed to capture.
Key levels
Key levels · DNB
NOK · as of 2026-08-22
Analyst consensus 310.08
R2317.5+1.5%
R1313.6+0.3%
S1303.32−3.0%
S2297.68−4.8%
S3294.54−5.8%
NOW312.7
Analyst consensus target 310.08 NOK · range 263.61–355.95
Key support & resistance and analyst consensus — educational analysis, not advice. These are not entry or exit prices. Trading involves risk of loss.
Key support sits at 303.32 (23.6% Fibonacci retracement of the 257.40–317.50 weekly swing) with the stronger floor at 297.68, the weekly EMA20 that has been tested and held twice since the Stage 2 uptrend began at the 257.40 low — The GARP Operator and the technical scout both cite this as the level where the balance of upside to downside resets favorably. Deeper support at 294.54 (38.2% retracement) and 282.23 (monthly 23.6% retracement of the 168.05–317.50 move) would come into play on any break of the EMA20. Key resistance is the 313.60–317.50 all-time-high zone, tested in the week ending 2026-08-16 on declining volume (0.89× the 10-week average), with thinning participation flagged by multiple voices as a negative divergence. The analyst consensus target of 310.08 sits below the current price of 312.70, confirming that the sell-side sees no upside from these levels.
What legendary investors think
We ran DNB Bank ASA past a panel of 6 legendary investors' frameworks.
The panel · 6 investors
🟢
0
Bullish
⚫
2
Neutral
🔴
4
Bearish
InvestorLensSignalConviction
The Moat CompounderValue/Quality/Moat🔴 BearishLow
Signal: DNB is a wonderful banking franchise, but at 1.63× book and 14.5× trailing earnings with zero earnings growth (PEG ratio of 194), the price already discounts perfection and leaves no margin of safety. Conviction: Conviction is tempered because the business quality score of 7/10 and the Norwegian government’s 34% stake provide a structural floor, making a severe permanent capital loss unlikely even at current levels.
The Margin-of-Safety HunterValue/Quantitative🔴 BearishLow
Signal: The stock trades at NOK 312.70 against a conservative The Margin-of-Safety Hunter Number of NOK 305.80, producing no margin of safety, and the P/B ratio of 1.62 exceeds the 1.5 threshold with no growth to justify the premium. Conviction: Confidence is undermined by missing data on earnings stability and dividend record, two pillars of the Margin-of-Safety Hunter framework that remain unconfirmed for this issuer.
The Intrinsic-Value ModelerValuation/DCF⚫ NeutralMed
Signal: A two-stage excess-return model places DNB’s base-case value at NOK 295, roughly 5.7% below the current price, implying the stock is slightly overvalued but within the model’s margin of error. Conviction: The base case rests on a stable 48% net margin and 1.7% revenue CAGR, assumptions that hold only if Norges Bank policy and credit quality remain steady.
The GARP OperatorGrowth (GARP)🔴 BearishLow
Signal: With a PEG ratio of 193.8 on 0.4% expected EPS growth, DNB is a classic Slow Grower trading at a full price that offers no cushion for a pullback from 52-week highs. Conviction: Thinning volume near all-time highs and consensus analyst targets below spot price add weight, but the buyback and Luminor capital release could create a floor if management accelerates capital return.
The Asymmetric BargainerContrarian/Deep Value🔴 BearishLow
Signal: DNB fails the core Dhandho test: at 1.6× book, downside is not sharply bounded — a recession could push the stock to 0.9–1.0× tangible book, a 40–50% loss, while upside is capped by zero growth. Conviction: The absence of any superinvestor cloning signal and the lack of a perception-versus-reality gap make this a pass with conviction.
The Forensic SkepticContrarian/Forensic⚫ NeutralLow
Signal: The TTM operating cash flow sits at negative 167 billion NOK against positive net income of 31 billion, a -5.3× OCF/NI ratio that signals deteriorating cash conversion behind the headline earnings. Conviction: The gap between price and fundamental reality is not yet wide enough to act on: the stock could stay range-bound for quarters while credit quality data remains opaque.
Each view is one investing framework applied to the stock — a perspective, not advice, and identical for every reader. Signals are the panel's own scale, not a recommendation to act.
Where they agree — and where they clash
Common ground
All six voices agree DNB’s business quality is high — a dominant Norwegian bank with a durable moat, scale advantages, and a 34% government stake providing stability.
No archetype argues the stock is cheap at NOK 312.70; every framework’s value estimate, target, or required entry sits at or below the current price.
Near-zero earnings growth (0.4–0.5% CAGR, PEG ~194) is the defining constraint that prevents any framework from justifying a premium multiple.
The buyback and Luminor capital return are acknowledged as positive capital-allocation moves, but none of the six sees them as transformative enough to alter the low-growth narrative.
The real debate
The Moat Compounder sees a wonderful business worth owning after a 20–25% pullback, while The Asymmetric Bargainer sees structurally unbounded downside that makes even a deep pullback insufficient without a catalyst to restore genuine asymmetry.
The Intrinsic-Value Modeler’s base case of NOK 295 suggests only mild overvaluation, whereas The GARP Operator’s PEG-based framework treats the 194× PEG as disqualifying at any price near current levels.
The question it comes down to: Will DNB’s negative operating cash flow and declining earnings catch up to the share price before a pullback to NOK 280–298 restores asymmetry?
The bottom line
Trigger to confirm the breakdown: A weekly close below the EMA20 at ~298 would validate the thinning-volume rally as a failed breakout and shift the technical structure from Stage 2 uptrend to distribution.
Price zone to re-engage: A pullback to NOK 280–298, where The Intrinsic-Value Modeler’s margin-of-safety zone, The GARP Operator’s buyable dip, and the conservative Margin-of-Safety Hunter Number converge, would restore asymmetry across multiple frameworks.
Next catalyst: Q3 2026 earnings (consensus ~NOK 6.46 EPS), with the Q2 miss of -4.85% still fresh; another miss paired with rising loan-loss provisions would harden the bear case.
Risk to monitor: The -5.3× OCF/NI divergence: if operating cash flow fails to normalize as loan origination slows, the earnings-quality question deepens beyond a mere accounting quirk into a credit-cycle concern.
To invalidate the bear case: A weekly close above 317.50 on rising volume would break the resistance zone and force all six frameworks to reassess, though the fundamental growth constraint remains intact.
Verdix's panel is made up of AI archetypes that apply the well-documented, publicly known investment frameworks of famous investors. They are AI agents — not the investors themselves. Verdix is not affiliated with, endorsed by, or authorized by any real individual, and the archetypes do not represent any real person's actual views, holdings, or statements. Every verdict is AI-generated.
Verdix provides educational equity research and AI-generated multi-perspective analysis. Nothing here constitutes personalized investment advice or a recommendation to buy or sell any security. Verdicts are uniform across all users and do not consider your individual financial situation, risk tolerance, or objectives. Trading and investing involve substantial risk of loss. Past performance does not predict future results. Consult a licensed financial advisor before making investment decisions.